Overview

AZD2014 and Weekly Paclitaxel in Squamous NSCLC

Status:
Terminated

Trial end date:
2016-12-29

Target enrollment:

Participant gender:

Summary

Open--label, phase 2a, multi-centre, single-arm study to assess the efficacy and safety of AZD2014 and weekly paclitaxel in patients with squamous non-small cell lung cancer (NSCLC)

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel